Dr. Francisco J Quintana will be presenting data on AnTolRx’s antigen-specific nanoparticle platform. Join us in Boston April 24-26, 2018. http://as-immunetolerance.com
We are excited to attend the 36th annual JP Morgan Healthcare Conference in San Francisco, CA from January 8th-11th,...
Goettel, J. et al. Cell Rep 17, 1318-1329(2016)
ASweetLife – Nanoparticles May Be Used to Treat Type 1 Diabetes “A couple of weeks ago I sat down with Dr. Francisco Quintana, who runs a lab at Brigham and Women’s Hospital in Boston focused on finding new treatments for autoimmune diseases. In...
CAMBRIDGE, Mass., September 8, 2016—AnTolRx, Inc. announced today that it has signed a Series A funding agreement with Pfizer Inc. (NYSE: PFE), Orion Equity Partners LLC and JDRF, the leading global organization funding type 1 diabetes (T1D) research. The funding...
Yeste, A. et al. Sci Signal 9, ra61(2016)
Mascanfroni, I. D. et al. Nat Immunol 14, 1054–1063 (2013).
Yeste, A., Nadeau, M., Burns, E. J., Weiner, H. L. & Quintana, F. J. Proc Natl Acad Sci USA 109, 11270–11275 (2012).
Quintana, F. J. et al. Proc Natl Acad Sci USA 107, 20768–20773 (2010).
Gandhi, R. et al. Nat Immunol 11, 846–853 (2010).